This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

References

Comments
Print

References

"Choosing Surface Disinfectants," by Kathryn Dix, page 14.

1. National Institutes of Health, Division of Safety. Biological decontamination: methods of disinfection. www.nih.gov/od/ors/ds/pubs/biodecontamination/biodecon1.htm. 08/07/02.

2. Crawford L, Yu Z, Keegan L, Yu T. A comparison of commonly used surface disinfectants. Infection Control Today. November 2000, 1-9.

3. OSHA. Frequently Asked Questions: Bloodborne Pathogens. www.osha-slc.gov/html/faq-bbp.html. 08/07/02.

4. Centers for Disease Control and Prevention. Sterilization or disinfection of patient-care equipment: HIV related. www.cdc.gov/ncidod/hip/Sterile/hivsteri.htm. 08/07/02.

5. Rutala WA. APIC guideline for selection and use of disinfectants. Am J Infect Control. 1996;24:313-342.

6. Rutala WA, Weber DJ. New disinfection and sterilization methods. Emerging Infect Diseases. 2001; 7(2): 348-53.

7. www.surfacine.com. 08/06/02.

Battling Biofilm: Surface Science, Antimicrobials Help Combat Medical Device-Related Infections," by Kelly M. Pyrek, page 32.

1. Katz J. Coating and surface treatment technology. www.devicelink.com/mddi/archive/97/04/019.html.

2. Lin TL, et al. Antimicrobial coatings: a remedy for medical device-related infections. www.medicaldevicesonline.com/features/story.epml?/features.REF=47.

3. Donlan RM. Biofilms and device-related infections. www.cdc.gov/ncidod/eid/vol7no2/donlan.htm.

4. Ibid.

5. Katz J. Coating and surface treatment technology. www.devicelink.com/mddi/archive/97/04/019.html.

6. Lin TL, et al. Antimicrobial coatings: a remedy for medical device-related infections. www.medicaldevicesonline.com/features/story.epml?/features.REF=47.  

7. Maki DG. Infections due to infusion therapy. In: Bennett JV, Brachman PS, eds. Hospital Infections. 3rd ed. Boston: Little, Brown; 1992.

8. Plott R, Polk B, Murdock B, et al. Mortality associated with nosocomial urinary tract infection. New Engl J Med. 30(11):637-642, 1982.

9. Watson SK, Lichtenberg DA, Wainwright H. Technology vs. the most common nosocomial infection. Infection Control Today. www.infectioncontroltoday.com/articles/081topics.html.

10. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. Ann Intern Med. 1997;127:267-74.

11. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. Ann Intern Med. 1997;127:267-74.

12. www.acponline.org/journals/annals/15aug97/cathedit.htm.

13. Davis RL and Etris SF. The development and functions of silver in water purification and disease control. The Silver Institute, Washington, D.C. www.silverfacts.org/pages/davies.html.

14. Silver-coated catheters cut infection. www.silverinstitute.org/silnews/1998/4b1998.htm.

15. Katz J. Coating and surface treatment technology. www.devicelink.com/mddi/archive/97/04/019.html

16. Rosenblatt AA and Knapp JE. Chlorine dioxide gas sterilization. HIMA Conference Proceedings, pp 47-50.

"Fighting the Flu," by Susan Dolan, RN, MS, CIC, page 46

1. American Academy of Pediatrics. 2000 red book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000:351-9.

2. Bolyard EA, Tablan OC, Williams WW, et al., for the Hospital Infection Control Practices Advisory Committee. Guideline for infection control in health care personnel. Am J Infect Control. 1998;26:289-354.

3. CDC. Prevention and control of influenza. Recommendations of the Advisory Committee On Immunization Practices (ACIP). MMWR 2002; 51(RR03):1-31.

4. CDC. Delayed influenza vaccine availability for the 2001-02 season and supplemental recommendations of the Advisory Committee on Immunization Practices [Notice to readers]. MMWR 2001;50:582-5.

5. Garner JS, for the Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol. 1996;17:53-80.

6. Hendrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J. 2000;19:410-17.

7. MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet. 1998;352:1877-81.

8. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis. 1999;180:254-61.

9. Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985--1990: the pediatric experience. Pediatr Infect Disease J. 2001;20:733-40.

10. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-33.

11. Internet resources:

www.cdc.gov/ncidod/diseases/flu/fluvirus.htm.

www.cdc.gov/nip/flu

Comments
comments powered by Disqus